Differences in mid-gestational and early postnatal neonatal cytokines and chemokines are associated with patterns of maternal autoantibodies in the context of autism
- 1 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 34 (13) , 50-62
Abstract
Associations between maternal immune dysregulation (including autoimmunity and skewed cytokine/chemokine profiles) and offspring neurodevelopmental disorders such as autism have been reported. In maternal autoantibody-related autism, specific maternally derived autoantibodies can access the fetal compartment to target eight proteins critical for neurodevelopment. We examined the relationship between maternal autoantibodies to the eight maternal autoantibody-related autism proteins and cytokine/chemokine profiles in the second trimester of pregnancy in mothers of children later diagnosed with autism and their neonates’ cytokine/chemokine profiles. Using banked maternal serum samples from 15 to 19 weeks of gestation from the Early Markers for Autism Study and corresponding banked newborn bloodspots, we identified three maternal/offspring groups based on maternal autoantibody status: (1) mothers with autoantibodies to one or more of the eight maternal autoantibody-related autismassociated proteins but not a maternal autoantibody-related autism-specific pattern, (2) mothers with a known maternal autoantibody-related autism pattern, and (3) mothers without autoantibodies to any of the eight maternal autoantibody-related autism proteins. Using a multiplex platform, we measured maternal second trimester and neonatal cytokine/chemokine levels. This combined analysis aimed to determine potential associations between maternal autoantibodies and the maternal and neonatal cytokine/chemokine profiles, each of which has been shown to have implications on offspring neurodevelopment independently.Keywords
Funding Information
- National Institutes of Health (P50MH106438, P50HD103526, R01ES016669)
This publication has 58 references indexed in Scilit:
- Neonatal immune signatures differ by sex regardless of neurodevelopmental disorder status: Macrophage migration inhibitory factor (MIF) alone reveals a sex by diagnosis interaction effectBrain, Behavior, and Immunity, 2023
- Cytokine see‐saw across pregnancy, its related complexities and consequencesInternational Journal of Gynecology & Obstetrics, 2022
- Eotaxin-1 (CCL11) in neuroinflammatory disorders and possible role in COVID-19 neurologic complicationsActa Neurologica Belgica, 2022
- Neonatal chemokine markers predict subsequent diagnosis of autism spectrum disorder and delayed developmentBrain, Behavior, and Immunity, 2022
- Peptides of neuron specific enolase as potential ASD biomarkers: From discovery to epitope mappingBrain, Behavior, and Immunity, 2020
- An Exploratory Examination of Neonatal Cytokines and Chemokines as Predictors of Autism Risk: The Early Markers for Autism StudyBiological Psychiatry, 2019
- Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia PatientsNeurotoxicity Research, 2018
- Identification of the antigenic epitopes of maternal autoantibodies in autism spectrum disordersBrain, Behavior, and Immunity, 2018
- Complexities in the Relationship Between Infection and AutoimmunityCurrent Allergy and Asthma Reports, 2013
- Maternal Mid-Pregnancy Autoantibodies to Fetal Brain Protein: The Early Markers for Autism StudyBiological Psychiatry, 2008